|Table of Contents|

Clinical efficacy of G-CSF plus GM-CSF and high-dose G-CSF for neutrophil deficiency after chemotherapy in acute myeloid leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 03
Page:
503-506
Research Field:
Publishing date:

Info

Title:
Clinical efficacy of G-CSF plus GM-CSF and high-dose G-CSF for neutrophil deficiency after chemotherapy in acute myeloid leukemia
Author(s):
ZHU Yuanxin; JIA Tao; MAO Jianping; MIAO Lei; ZHAO Lidong; WANG Ying
The First People's Hospital of Lianyungang,Jiangsu Lianyungang 222001,China.
Keywords:
G-CSF; GM-CSF; acute myeloid leukemia
PACS:
R733.7
DOI:
10.3969/j.issn.1672-4992.2023.03.022
Abstract:
Objective:To explore the clinical efficacy and safety of high-dose G-CSF regimen and G-CSF plus GM-CSF regimen for patients with acute myeloid leukemia(AML) after chemotherapy in the treatment and prevention of neutrophil deficiency.Methods:We retrospectively analyzed 53 AML patients who received chemotherapy,compared standard-dose G-CSF regimen,high-dose G-CSF regimen,and G-CSF plus GM-CSF regimen used in these patients after chemotherapy,observed the absolute neutrophil count,duration of neutropenia,the probability of febrile neutropenia,and adverse reactions in 3 groups.Results:Compared with the standard-dose G-CSF group,the high-dose G-CSF group and the G-CSF plus GM-CSF group significantly shortened the median duration of ANC reduction and the incidence of febrile neutropenia.There was no statistical difference between the high-dose G-CSF group and G-CSF plus GM-CSF group,and the safety among the three groups was similar.Conclusion:Both G-CSF combined with GM-CSF regimen and high-dose G-CSF regimen were safe and effective to treat and prevent neutrophil deficiency after chemotherapy in AML.

References:

[1]DAMODARAN N,OLGA K.How I investigate acute myeloid leukemia［J］.Int J Lab Hematol,2020,42(1):3-15.
[2] PELCOVITS A,NIROULA R.Acute myeloid leukemia:A review［J］.R I Med J,2020,103(3):38-40.
[3] HARTMUT D,ELIHU E,DAVID G,et al.Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel［J］.Blood,2017,129(4):424-447.
[4] KLEPIN HD.Elderly acute myeloid leukemia:Assessing risk［J］.Curt Hematol Malig Rep,2015,10(2):118-125.
[5]中国医师协会肿瘤医师分会.中国重组人粒细胞集落刺激因子在肿瘤化疗中的临床应用专家共识(2015年版) ［J］.中华医学杂志,2015,95(37):3001-3003. Oncologists Branch of Chinese Medical Association.Expert consensus on clinical application of recombinant human granulocyte colony stimulating factor in tumor chemotherapy(2015) ［J］.Chinese Medical Journal,2015,95(37):3001-3003.
[6]中国临床肿瘤学会指南工作委员会.肿瘤放化疗相关中性粒细胞减少症规范化管理指南［J］.中华肿瘤杂志,2017,39(11):868-878. Guidelines Working Committee of Chinese Society of Clinical Oncology.Guidelines for standardized management of neutropenia associated with chemoradiotherapy［J］.Chinese Journal of Oncology,2017,39(11):868-878.
[7] KLASTERSKY J,DE NAUROIS J,ROLSTON K,et al.Management of febrile neutropaenia:ESMO Clinical Practice Guidelines［J］.Ann Oncol,2016,27(5):v111-v118.
[8] DINARDO CD,PRATZ K,PULLARKAT V,et al.Venetoclax combined with decitabine or azacitidine in treatment-naive,elderly patients with acute myeloid leukemia［J］.Blood,2019,133:7-17.
[9] ARNDT C,FELDMANN A,KORISTKA S,et al.Improved killing of AML blasts by dual-targeting of CD123 and CD33 via UniTARG a novel antibody-based modular T cell retargeting system［J］.Blood,2015,126:2565.
[10]中华医学会血液学分会白血病淋巴瘤学组.成人急性髓系白血病（非急性早幼粒细胞白血病）中国诊疗指南（2017年版）［J］.中华血液学杂志,2017,38(3):177-182. Leukemia and Lymphoma Group,Hematology Branch,Chinese Medical Association.Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia(non acute promyelocytic leukemia)(2017) ［J］.Chinese Journal of Hematology,2017,38(3):177-182.
[11] CERCHIONE C,DE RENZO A,NAPPI D,et al.Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support［J］.Support Care Cancer,2019,27(5):1587-1588.
[12] LYMAN GH,DALE DC,WOLFF DA,et al.Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor:a systematic review［J］.J Clin Oncol,2010,28(17):2914-2924．
[13] FENG XQ,LAN H,RUAN YS,et al.Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application:a meta-analysis［J］.Hematology,2018,23(9):581-589.
[14] BENGUERFI S,THEPAULT F,LENA H,et al.Spontaneous splenic rupture as a rare complication of G-CSF injection［J］.BMJ Case Rep,2018,2018:bcr2017222561.
[15] YAN WL,SHEN KY,TIEN CY,et al.Recent progress in GM-CSF-based cancer immunotherapy［J］.Immunotherapy,2017,9(4):347-360.

Memo

Memo:
-
Last Update: 2022-12-30